Europital, a full service CRO serving small and mid-tier innovators, has significantly expanded with the launch of new capabilities across project management, clinical monitoring, biostatistics, pharmacovigilance, regulatory affairs and data management, in addition to its existing services of Medical Affairs and Medical Writing. The expanded clinical research offering will support full CRO services in more than 40 countries from IND through to commercial launch.

“We are delighted to announce that we can now provide a full, 360-degree CRO service to innovators in the pharmaceutical, biotechnology and medical devices sectors. Europital has seen a robust expansion in the last few years, and we have been steadily preparing to launch full service capabilities. It’s no secret, there is a large gap in the CRO industry for these small innovators; what they need is a science-driven CRO that will support them closely with an experienced senior team but combined with a global trial network. We’re very excited to be able to further support our current partners and many of the new innovators bringing vital therapies to patients,” said Dr. Mohamed El Malt, Chief Medical Officer of Europital.

Europital has regional offices in Belgium, Hungary and the UK and their customers are based in both Europe and the U.S. Innovators developing therapies for oncology, infectious diseases, inflammatory and autoimmune diseases will be the major beneficiaries of Europital’s multi-functional and operational capabilities. Sponsors will have access to a full range of CRO services for complex molecules and trial designs that necessitate senior medical and scientific oversight.

“The decision to launch as a full-service CRO reflects the many requests we have had from our clients over the years to work on additional aspects of their clinical trials, but the services for which we did not have in-house. Now we are able to support them throughout the whole trial process. Our goal is to continue building our partnerships to become the leading science-based CRO for small to mid-sized pharma and biotech companies,” added Dr. El Malt.